TREA

97716240 - ALLO-GLUE

Follow

Information

  • Trademark
  • 97716240
  • Serial Number
    97716240
  • Filing Date
    December 13, 2022
    a year ago
  • Transaction Date
    June 13, 2024
    4 months ago
  • Status Date
    June 11, 2024
    4 months ago
  • Published for Opposition Date
    October 31, 2023
    a year ago
  • Location Date
    December 26, 2023
    10 months ago
  • Status Code
    730
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    NODES, CHRISTOPHER JAM
  • Attorney Docket Number
    114384-0005
    Law Office Assigned Location Code
    M70
  • Owners
Information
Mark Drawing Code
4
Mark Identification
ALLO-GLUE
Case File Statements
  • GS0051: Pharmaceutical products, serums and preparations for the treatment of cancer, auto immune disorders, metabolic disorders, neurological disorders, neuromuscular disorders; Biochemical preparations for medical purposes for use in the treatment of cancer, auto immune diseases, metabolic diseases, neurological diseases, neuromuscular diseases
  • PM0001: ALLOW GLUE
  • GS0011: Diagnostic and chemical reagents for scientific and research use; pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; Active chemical ingredients for use in the manufacture of small molecule pharmaceuticals for treating cancer, auto immune diseases, metabolic diseases, neurological diseases, neuromuscular diseases
  • GS0421: Development of new technology for others in the field of biotechnology; scientific research and laboratory research services in the medical, bacteriological and biotechnical fields; biotechnical research; technical consultation and research in the field of biotechnological research; Consulting services in the fields of biotechnology and pharmaceutical research and development; consulting services in the field of laboratory testing for scientific purposes in the field of pharmaceuticals and biotechnology; consulting services in the field of research and development of new products relating to diagnosis of diseases; consulting services in the field of pharmacogenetics; research and development of pharmaceuticals for others; scientific and medical research in the fields of oncology, immunology and immune-oncology, inflammation, immune-mediated diseases, protein homeostasis, epigenetics and protein metabolism
Case File Event Statements
  • 9/16/2023 - a year ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 12/16/2022 - a year ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 1/10/2023 - a year ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 9/22/2023 - a year ago
    4 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 9/22/2023 - a year ago
    5 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 9/22/2023 - a year ago
    6 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 9/22/2023 - a year ago
    7 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 9/22/2023 - a year ago
    8 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 10/11/2023 - a year ago
    9 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 10/31/2023 - a year ago
    10 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 10/31/2023 - a year ago
    11 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 12/26/2023 - 10 months ago
    12 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 6/11/2024 - 4 months ago
    13 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 6/11/2024 - 4 months ago
    14 - SOU EXTENSION 1 FILED Type: EXT1
  • 6/11/2024 - 4 months ago
    15 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 6/13/2024 - 4 months ago
    16 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA